TradersLink
$PPCBJun 16, 2026, 8:45 AM ETAI processed

Propanc tours European CDMO; sets Aug/Oct/Dec 2026 timetable for GMP PRP ahead of Phase 1b (30–40 pts)

AI Summary

Propanc's CEO visited a European CDMO and the company announced target dates to prepare PRP for its planned Phase 1b first-in-human trial: preproduction in Aug 2026, an engineering run in Oct 2026, and GMP manufacture starting Dec 2026, with four weeks of stability data expected to support an Australian clinical trial application in 2026. PRP is an IV weekly fixed combination of two proenzymes (trypsinogen and chymotrypsinogen); securing a CDMO partner and defining a near-term manufacturing timetable reduces a key operational hurdle ahead of dosing but execution risks and regulatory acceptance remain.

Positives

  • Targeted manufacturing timeline: preproduction Aug 2026, engineering run Oct 2026, GMP manufacture Dec 2026
  • Plans to supply PRP for a planned Phase 1b FIH trial in 30–40 advanced solid tumor patients
  • Company expects four weeks of stability data post-engineering run could support an Australian trial application in 2026

Negatives

  • Announced dates are targets and forward-looking, not confirmed completions
  • No GMP batches have been produced yet; engineering run and full GMP manufacture are still pending
  • Clinical trial application has not yet been filed and remains subject to regulator acceptance